Skip to content

GU

4 interviews

ASCO Genitourinary Cancers Symposium

Interviews and expert commentary from GU — study authors and key opinion leaders discuss the findings and their clinical implications.

Adjuvant Chemotherapy Extends Life in Locally Advanced Bladder Cancer

Adjuvant Chemotherapy Extends Life in Locally Advanced Bladder Cancer

ORLANDO—Adjuvant chemotherapy was found to extend life in patients with locally advanced bladder cancer in research reported to the 2015 Genitourinary Cancers Symposium. Matt Galsky MD from the Tisch

13 March 2015
Castration-resistant prostate cancer with bone metastases: long follow up shows radium is safe as well as effective

Castration-resistant prostate cancer with bone metastases: long follow up shows radium is safe as well as effective

SAN FRANCISCO—New research has shown the alpha-emitting drug radium 233 to be a “benign” therapy with no major toxicities — while effectively targeting bone metastatic disease and increasi

11 March 2014
Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too

Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too

ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM stu

24 March 2013
Low risk localized prostate cancer: no harm from waiting!

Low risk localized prostate cancer: no harm from waiting!

ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Sympo

24 March 2013